PLx Pharma: Rises as FDA approves Vazalore in two dose strengths

PLx Pharma Winddown

01/03/2021 13:28

** Drug developer's shares  PLXP.O  up 18% at $8.5 premarket
    ** Co says the U.S. FDA has approved its lead drug,
Vazalore, in two dose strengths
    ** Says the marketing approvals are for Vazalore 325 mg and
Vazalore 81 mg, liquid-filled aspirin capsule  urn:newsml:reuters.com:*:nGNX4GNQrV
    ** U.S. commercial launch of Vazalore planned for third
quarter 2021 - PLXP
    ** Aspirin is an antiplatelet agent and can reduce the risk
of blood clots
    ** Up to Friday's close, stock had risen 43% in the last 12
months

 (Reporting by Dania Nadeem in Bengaluru)
 ((Dania.Nadeem@thomsonreuters.com;))